Technology updates - Clinuvel Pharmaceuticals

Technology updates

Technology Update III

Stem cells and repigmentation in vitiligo An exploration of the in-depth science that underpins Clinuvel’s vitiligo program Friday May 13, 2011Download PDF format Cellular messaging: receptors, ligands and signaling pathways Each cell within the body has one or more receptors; molecules on or within the cell to which other molecules, called ligands (such as peptides), bind. This binding causes changes within the cell which normally follow set ‘signaling’ pathways. Signaling pathways are responsible for cellular responses, allowing other cells and external elements to alter how a cell functions. There…

Technology Update II

Afamelanotide as an adjunct to phototherapy Thursday 22 April, 2010 Phototherapy – an overview A number of severe skin disorders are treated by phototherapy, light therapy applied at certain wavelengths. The therapeutic effect of dosed light sources on a number of skin disorders such as psoriasis, polymorphous light eruption, solar urticaria and vitiligo is well demonstrated. Clinuvel is developing afamelanotide as a photoprotective agent in a variety of skin disorders, of which erythropoietic protoporphyria (EPP) is the indication most advanced in its clinical development. EPP is being treated as an injectable…

Technology Update I

The physiological "UV tanning response", original thoughts on UV and pigmentation Friday February 5, 2010 UV light penetrates melanocompromised skin and causes damage. During the late eighties, various scientists simultaneously worked on and developed a number of analogues of alpha-melanocyte stimulating hormone (α-MSH) to study the effect of these molecules on dermal UV-protection. As a matter of fact, the Arizona group initially received funding from the NIH specifically to develop melanoma prevention strategies. It was well documented that physiological α-MSH played an important role in the natural pigmentary response following…

Technology Updates

As part of a new series of updates on technology, and to complement on Clinuvel's public news flow, Clinuvel has initiated a regular bulletin to provide its followers worldwide with the latest advances on relevant issues, such as environmental factors, skin and related biochemical issues. These discussions aim to increase the understanding of the science and technology behind Clinuvel’s progress in pharmaceutical development. Where the depth of information becomes too profound we have tried to summarise concepts into easier terms. Technology Update I - The physiological "UV tanning response", original…

SCENESSE® Spotlight

SCENESSE® as a repigmentation therapy

Clinuvel is currently conducting two clinical trials to evaluate the efficacy of SCENESSE® as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy compared to NB-UVB alone. The goal of these trials is to determine whether SCENESSE® will reduce the total dose of radiation (NB-UVB) and the time required to reactivate skin pigment producing cells in ...